Peter Carmeliet
From Wikipedia, the free encyclopedia
Peter Carmeliet is a Belgian MD and professor at the Katholieke Universiteit Leuven (Leuven, Belgium). He is also Adjunct Director of the VIB Department of Transgene Technology and Gene Therapy, K.U.Leuven. One of his research interests are vasculogenesis, angiogenesis and Vascular endothelial growth factor (VEGF)[1][2][3].
[edit] Awards
- 2002: Francqui Prize on Biological and Medical Sciences.
- 2005: Interbrew-Baillet Latour Health Prize, together with Désiré Collen[4].
[edit] References
- ^ Carmeliet P, Ferreira V, Breier G, Pollefeyt S, Kieckens L, Gertsenstein M, Fahrig M, Vandenhoeck A, Harpal K, Eberhardt C, Declercq C, Pawling J, Moons L, Collen D, Risau W, Nagy A, Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele, Nature 380, 435-439, 1996
- ^ Ferrara N, Carver-Moore K, Chen H, Dowd M, Lu L, O’Shea KS, Powell-Braxton L, J. Hillan K, W. Moore M, Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene, Nature 380, 439-442, 1996
- ^ Fischer C, Jonckx B, Mazzone M, Zacchigna S, Loges S, Pattarini L, Chorianopoulos E, Liesenborghs L, Koch M, De Mol M, Autiero M, Wyns S, Plaisance S, Moons G, Van Rooijen N, Giacca M, Stassen J, Dewerchin M, Collen D, Carmeliet P, Anti-PlGF Inhibits Growth of VEGF(R)-Inhibitor-Resistant Tumors without Affecting Healthy Vessels, Cell 131, 463-75, 2007
- ^ Bloom S., Belgian scientists awarded top honors, J Clin Invest. 2005 May;115(5):1106-7
[edit] External links
This Belgian biographical article is a stub. You can help Wikipedia by expanding it.
